Buying a Pharmacy With an Open PBM Audit

A pharmacy acquisition where the target has an open PBM audit is common, not disqualifying, but it changes how the deal has to be built. An OptumRx, CVS Caremark, or Express Scripts audit still open at signing carries an unresolved recoupment demand that can run into six or seven figures, and that exposure does not disappear because ownership changes hands. Whether the buyer inherits it depends on the deal structure, the purchase agreement, and whether the PBM's own network agreements survive a change of ownership at all. Diligence on an open audit belongs at the letter of intent stage, not after closing.

Successor Liability in Asset and Stock Deals

Deal structure is the first lever. In a stock purchase, the buyer acquires the target entity itself, so every liability it carries, including an open PBM audit and its recoupment, comes with the transaction. In an asset purchase, the buyer selects specific assets and liabilities and can leave the audit with the selling entity, which is why most pharmacy buyers default to an asset structure once a known audit is on the table. That structure is not a complete answer. Courts in a number of states recognize exceptions to the rule that an asset buyer does not inherit the seller's liabilities, including a de facto merger or a mere continuation of the seller's business. A PBM can also treat the change of ownership as its own trigger for reviewing pending recoupment, regardless of how state successor liability law comes out, because the PBM's remedy runs through the provider agreement, not a court's analysis.

Structuring the Deal Around Known Exposure

Once the audit is disclosed, the purchase price and closing mechanics should account for it directly. A defined dollar reduction tied to the PBM's stated demand is the most direct fix. An escrow holdback, funded from the seller's proceeds and released once the audit resolves, is the more common approach when the final recoupment number is not yet known. The escrow term should track the audit's actual appeal deadlines rather than a generic 12- or 18-month window, since a multi-level PBM appeal can outlast a standard holdback. The agreement should also state who controls the audit response after closing. A seller who signs away that control while remaining financially responsible for the outcome loses the ability to defend the number its escrow will be measured against.

An open PBM audit does not need to be resolved before a pharmacy sale closes, but every dollar of undefined recoupment exposure left out of the purchase agreement becomes the buyer's problem the day the deal closes.

Due Diligence and Audit Disclosure

The representations and warranties section is where an open audit gets fully disclosed, or becomes the basis for a later indemnification claim. A seller representation that no audit or recoupment demand is pending, when one in fact is, gives the buyer a breach claim, but recovering after the fact is weaker than pricing the risk up front. Diligence should pull the pharmacy's full PBM audit history, not only the open matter, since a pattern of prior findings on the same billing practice raises the odds an extrapolated demand survives appeal. Diligence should also confirm which legal entity the audit notice named, since the asset buyer's protection depends on it.

PBM Change of Ownership and Network Assignment

Separate from the recoupment itself, the change of ownership has to satisfy each PBM's own contract terms or the buyer risks losing the ability to bill the network. Most PBM provider agreements restrict assignment and require advance notice, a change of ownership submission, or full recredentialing before a new owner can submit claims. An asset sale is more likely to trigger recredentialing than a stock sale, since the acquiring entity, and often its National Provider Identifier, is new to the PBM. Recredentialing is not automatic. A pharmacy that closes without confirming each PBM's requirements can find itself unable to adjudicate claims for weeks, on top of the audit itself.

Why Early Legal Counsel Is Critical

It is critical that a buyer or seller retain experienced healthcare defense counsel as soon as an open PBM audit surfaces in diligence, and before the letter of intent is signed. Early legal involvement can shape how the audit is disclosed, priced, and allocated between the parties, protect each side's rights during the audit's own appeal timeline, and prevent the purchase agreement from leaving a gap that later becomes an uninsured loss.

How Health Law Alliance Can Help

Health Law Alliance has represented 2,500+ clients over 25+ years, including pharmacy owners buying or selling a business with an open PBM audit in the mix. Our PBM audit defense attorneys review the audit, negotiate deal terms that allocate its risk, and carry the audit response through to resolution. Contact Health Law Alliance for a free, confidential consultation.